Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts
Abigail Shea(Institute of Cancer Research), Alejandra Bruna(Institute of Cancer Research), Martin O’Reilly(Cancer Research UK), Daniel Guerrero-Romero(University of Cambridge), Dimitra Georgopoulou(University of Cambridge), Jean Abraham(Cancer Research UK), Louise Grybowicz(Cambridge University Hospitals NHS Foundation Trust), Jonny Lay(University of Cambridge), Sophia Wix(University of Cambridge), Agnese Giovannetti(Agostino Gemelli University Polyclinic), Karen McAdam(Peterborough City Hospital), Elham Esmaeilishirazifard(AstraZeneca (United Kingdom)), Helen Bardwell(University of Cambridge), Raquel Manzano García(University of Cambridge), Giulia Lerda(University of Cambridge), Maurizio Callari(Fondazione IRCCS Istituto Nazionale dei Tumori), Justine M. Kane(University of Cambridge), Alistair Martin(University of Cambridge), A. Nagano(The Francis Crick Institute), Riccardo Masina(University of Cambridge), Elena Provenzano(University of Cambridge), Steven Kupczak(Cancer Research UK Cambridge Center), Yaniv Eyal-Lubling(University of Cambridge), Carlos Caldas(Université Libre de Bruxelles), Yi Cheng(University of Cambridge), Oscar M. Rueda(University of Cambridge), Lisa Young(University of Cambridge), Wendy Greenwood(University of Cambridge)
Cited by 0
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Lung adenocarcinoma promotion by air pollutants
|Nature|2023|751
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
|Annals of Oncology|2018|424
Cohesin‐mediated interactions organize chromosomal domain architecture
|The EMBO Journal|2013|412